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An Important Mediator of Thrombus Formation
and Cardiovascular RiskOsita N. Okafor, BSC, MBBS,* Diana A. Gorog, MBBS, MD, PHD*yABSTRACTFro
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MaMost acute cardiovascular events are attributable to arterial thrombosis. Plaque rupture or erosion stimulates platelet
activation, aggregation, and thrombosis, whilst simultaneously activating enzymatic processes that mediate endogenous
ﬁbrinolysis to physiologically maintain vessel patency. Interplay between these pathways determines clinical outcome. If
proaggregatory factors predominate, the thrombus may propagate, leading to vessel occlusion. However, if balanced by
a healthy ﬁbrinolytic system, thrombosis may not occur or cause lasting occlusion. Despite abundant evidence for the
ﬁbrinolytic system regulating thrombosis, it has been overlooked compared with platelet reactivity, partly due to a lack
of techniques to measure it. We evaluate evidence for endogenous ﬁbrinolysis in arterial thrombosis and review tech-
niques to assess it, including biomarkers and global assays, such as thromboelastography and the Global Thrombosis
Test. Global assays, simultaneously assessing proaggregatory and ﬁbrinolytic pathways, could play a role in risk strati-
ﬁcation and in identifying impaired ﬁbrinolysis as a potential target for pharmacological modulation. (J Am Coll Cardiol
2015;65:1683–99) © 2015 by the American College of Cardiology Foundation. Open access under CC BY-NC-ND licenseC ardiovascular disease is the leading cause ofmorbidity and mortality in developed coun-tries. The common pathological process
responsible for the majority of these disorders, in-
cluding acute coronary syndrome (ACS) and ischemic
stroke, is the development of an occlusive arterial
thrombus.
Disruption of an atherosclerotic plaque through
rupture or erosion creates a prothrombotic envi-
ronment to circulating platelets and procoagulant
factors. The major thrombogenic components con-
tainedwithin the atherosclerotic plaque include tissue
factor and collagen (1–3). Exposure to this thrombotic
milieu provides a potent stimulus for platelet activa-
tion, aggregation, and thrombosis (Figures 1A and 1B).m the *East & North Hertfordshire NHS Trust, Hertfordshire, United King
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direct activation of the enzymatic processes that
mediate endogenous ﬁbrinolysis (Figure 1C). This
interaction is important to ensure that thrombosis is
controlled and vessel patency is maintained.
The interplay between these opposing pathways
is likely to determine the occurrence and clinical
outcome of a resulting thrombus. If proaggregatory
and procoagulant factors predominate, an intra-
luminal thrombus may propagate and lead to com-
plete vessel occlusion, with subsequent lasting
downstream tissue damage (Figure 1B). If, in contrast,
the prothrombotic factors are balanced by a healthy
ﬁbrinolytic system, then a thrombus may not develop
or may not cause lasting vessel occlusion (Figure 1C).dom; and yVascular Sciences, National Heart & Lung
to a company director of Thromboquest Ltd., who
ren have no ﬁnancial involvement or equity interest
oquest Ltd. Thromboquest Ltd. has no involvement
that he has no relationships relevant to the contents
ntin Fuster.
r. Valentin Fuster.
20, 2015, accepted February 23, 2015.
ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome(s)
AMI = acute myocardial
infarction
GTT = Global Thrombosis Test
MACE = major adverse
cardiovascular event(s)
PAI = plasminogen
activator inhibitor
ROTEM = rotational
thromboelastometry
SR = spontaneous reperfusion
STEMI = ST-segment elevation
myocardial infarction
TAFI = thrombin-activatable
ﬁbrinolysis inhibitor
TEG = thromboelastography
t-PA = tissue-type
plasminogen activator
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1684IMPORTANCE OF THE ENDOGENOUS
FIBRINOLYTIC SYSTEM IN ACS
An intact endogenous ﬁbrinolytic system
serves to actively prevent the buildup of
formed thrombi through dissolution of
an arterial thrombus (Central Illustration).
Despite a wealth of evidence supporting
its role in preventing lasting arterial occlu-
sion, this pathway has been relatively over-
looked as compared with the understanding,
monitoring, and pharmacological modulation
of platelet reactivity. This may have occurred
due to limitations of earlier methods to
robustly measure the activity of the ﬁbrino-
lytic system. Additionally, besides the use of
plasminogen activators to achieve acute
thrombolysis in the setting of acute myocar-
dial infarction (AMI) and stroke, pharmaco-
logical options available to manipulate the
ﬁbrinolytic state have been very limited.Evidence from clinical, histopathologic, and au-
topsy studies (4–9), as well as clinical observations,
support the proposal that AMI may represent a
failure of timely, spontaneous endogenous throm-
bolysis. In 585 patients presenting with ST-segment
elevation myocardial infarction (STEMI), sponta-
neous reperfusion (SR), evidenced by electrocardio-
graphic resolution of ST-segment changes, was
observed in 14.9%, and normal coronary ﬂow on
angiography was observed in 14.7% of patients (10).
In 1,667 patients assigned to the primary percuta-
neous coronary intervention arm of the ASSENT 4
(Assessment of the Safety and Efﬁcacy of a New
Treatment Strategy for Acute Myocardial Infarction)
trial (11), SR was associated with a lower composite
of death, heart failure, or shock compared with
those with persistent ST-segment elevation. In 710
STEMI patients undergoing primary percutaneous
coronary intervention, SR was observed in 22%, and
these patients had a lower incidence of death,
congestive heart failure, and recurrent ACS at 30
days than those without SR (12). Furthermore, his-
topathologic studies evaluating aspirated coronary
thrombi from patients with STEMI have demon-
strated signiﬁcant heterogeneity in the composition
and age of the culprit thrombi (4–7). Among 1,362
STEMI patients, up to 40% demonstrated lytic or
organized thrombi, signifying that thrombus forma-
tion occurred days to weeks before ﬁnal vessel oc-
clusion (7). This underpins the notion that thrombus
generation is an active and dynamic process, where
constant thrombosis and thrombolysis may occur in
concert.Autopsy studies of healed plaque disruptions also
provide evidence of thrombus formation as a dynamic
process (8,13). Plaque instability appears to be pre-
sent for some time before an occlusive thrombus is
formed, and may be asymptomatic. Nonocclusive
mural thrombi may form over plaque disruptions,
leading to phasic progression of atherosclerotic le-
sions, but without presenting as ACS (13,14).
Despite the fact that plaque rupture represents a
common unifying event for coronary thrombosis,
there is signiﬁcant variability in clinical manifesta-
tion and outcome. This variability may be explained,
in part, by the role of endogenous ﬁbrinolysis in
limiting the propagation of formed thrombi and pre-
venting total coronary occlusion (Central Illustration).
In this paper, we review the methods currently
available to assess endogenous ﬁbrinolysis and eval-
uate the evidence for the role of endogenous ﬁbri-
nolysis as a mediator of arterial thrombus formation
in coronary disease.FACTORS DETERMINING RESISTANCE OF
THROMBUS TO LYSIS
Whole blood clots are more resistant to lysis than
plasma clots, implying that blood cells and ﬁbrin are
responsible for the resistance (15) (Central
Illustration). Platelets play the main role in resis-
tance, but red cell–derived microparticles can also
contribute to thrombin generation, whereas elastase
released from leukocytes trapped or adherent to the
thrombus exerts a plasmin-independent ﬁbrinolytic
effect. Arterial (platelet-rich) thrombi are much more
resistant to lysis than erythrocyte-rich venous
thrombi (16). The mechanisms through which plate-
lets contribute to thrombolysis resistance are 3-fold
(Central Illustration):
1. Platelets contain >90% of the circulating plasmin-
ogen activator inhibitor (PAI)-1. During aggrega-
tion, in response to thrombin, PAI-1 is released
from platelets into the thrombus mass and is the
major determinant of arterial thrombolysis resis-
tance (17).
2. The procoagulant activity or contribution of
platelets to thrombin generation is extremely
important, not only in the generation of, but also in
the lysis of the formed thrombus. A high shear
stress milieu, such as that found in an artery with a
severe stenosis, will trigger microparticle release
from activated platelets, resulting in a burst of
thrombin generation. In addition to PAI-1,
thrombin-activatable ﬁbrinolysis inhibitor (TAFI)
also contributes to thrombolysis resistance.
FIGURE 1 The Mechanism and Importance of Endogenous Fibrinolysis in Regulation of Occlusive Arterial Thrombus Formation, and its Relevance to
Laboratory Tests Assessing Thrombotic Risk
(A) Under conditions of high shear, such as those that exist in a narrowed coronary artery, stimulation of platelet aggregation by von Willebrand Factor (vWF) results in
the formation of thrombin, the key mediator of thrombus formation. (B) The thrombus achieves structural stability and resistance to dislodgement and to thrombolysis
through ﬁbrin (which crosslinks cells to provide structural stability), plasminogen activator inhibitor (PAI)-1 released from activated platelets, and activation of thrombin-
activatable ﬁbrinolysis inhibitor (TAFI) by thrombin. (C) Endogenous thrombolysis: physiological processes that exist to prevent lasting occlusive thrombus formation,
including the release of tissue plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA) from the vessel wall and plasma, the release of elastase and
cathepsin from adherent neutrophils and monocytes, and the dispersing effect of ﬂow. ADP ¼ adenosine diphosphate; TxA2 ¼ thromboxane A2.
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CENTRAL ILLUSTRATION Endogenous Thrombolysis in CV Disease: Determinants of Spontaneous Thrombolysis Under
Arterial Flow Conditions
Thrombin converts plasminogen to plasmin, which breaks down the cross-linked ﬁbrin into soluble ﬁbrin degradation products. t-PA is mainly responsible
for the dissolution of ﬁbrin formed in the circulation. Inhibitors of thrombolysis include the release of PAI-1 from platelets, secretion of active PAI-1 from
aggregated platelets, and clot retraction. Potentiators of thrombolysis include: the release of elastase and cathepsin G from white blood cells that become
trapped in the thrombus, which directly break down ﬁbrin; the plasminogen activators uPA and t-PA (released from endothelial cells); and ﬁbrin structural
properties. The thickness and porosity of ﬁbrin ﬁbers will also determine structural stability and susceptibility to thrombolysis. Lp(a), a homologue of
plasminogen, can inhibit t-PA–mediated plasminogen activation. aTAFI ¼ activated thrombin-activatable ﬁbrinolysis inhibitor; CV ¼ cardiovascular; EC ¼
endothelial cell; FXIII ¼ coagulation factor XIII; Lp(a) ¼ lipoprotein (a); PAI-1 ¼ plasminogen activator inhibitor; PAR ¼ protease-activated thrombin re-
ceptor; TAFI ¼ thrombin-activatable ﬁbrinolysis inhibitor; t-PA ¼ tissue plasminogen activator.
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network is also a determinant of thromboresis-
tance (18). Platelets play an important role in
regulating ﬁbrin network structure (19). Coagula-
tion factor XIII (FXIII), in addition to cross-linking
ﬁbrin, also plays an important role in thrombol-
ysis resistance. Platelets are abundant in FXIII, and
upon activation, FXIII-A exposure on the surface
membrane exerts an antiﬁbrinolytic function by
cross-linking the major plasmin inhibitor a2-
antiplasmin to ﬁbrin, thus inhibiting plasmin-
mediated clot degradation (20,21). FXIII alters the
structure of the ﬁbrin network to reduce pore sizeand increase ﬁber density, thus increasing clot
stability and resistance to lysis (22). Thrombi
formed in FXIII-deﬁcient blood lyse more quickly
than in normal blood, and FXIII concentrate
normalized lysis (23). A common genetic poly-
morphism of FXIII has been shown to increase the
risk of myocardial infarction (24).
MEASUREMENT OF FIBRINOLYTIC STATUS
Interest in the endogenous ﬁbrinolytic system has
fueled the development of techniques to assess and
quantify the activity of this important pathway. Many
TABLE 1 Comparison of Thromboelastography (ROTEM) and the GTT, With
Respect to Assessment of Thrombosis
Measurement ROTEM GTT
Thrombus Cross-linked ﬁbrin clot Platelet-rich ﬁbrin clot
Relevance Venous thrombosis Arterial thrombosis
Flow (shear rates/s) Static (0.1/s) High shear (>10,000/s)
Blood sample Citrate-anticoagulated Native blood
Thrombus resistance No Yes
PAI-1 involvement in lysis No Yes
Platelets procoagulant
effect
Little Signiﬁcant
Activator Tissue factor/kaolin (extrinsic
and intrinsic coagulation
pathways)
High shear stress only
Hyperﬁbrinolysis (t-PA) Yes Yes
Hypoﬁbrinolytic state No Yes
GTT ¼ global thrombosis test; PAI-1 ¼ plasminogen activator inhibitor-1; ROTEM ¼ rotational
thromboelastometry; t-PA¼ tissue-type plasminogen activator.
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vided compelling evidence of endogenous ﬁbrinolysis
in arterial thrombogenesis, although no current test
has been adopted into widespread clinical use.
Current techniques include: 1) the measurement of
1 or several protein components of the ﬁbrinolytic
cascade; or 2) global assessment of ﬁbrinolytic ca-
pacity utilizing techniques such as euglobulin clot
lysis time, thromboelastography (TEG) (Haemoscope
Corporation, Niles, Illinois) or rotational thromboe-
lastometry (ROTEM) (Tem International GmbH,
Munich, Germany), and the most recent Global
Thrombosis Test (GTT) (Thromboquest Ltd., London,
United Kingdom). These techniques are described in
more detail in the following text.
PLASMA MARKERS OF FIBRINOLYSIS
The ﬁbrinolytic system shares several similarities
with the coagulation cascade, involving a series of
proteolytic enzymatic steps that culminate in the
conversion of plasminogen to plasmin to achieve
ﬁbrin dissolution (Figure 1C, Central Illustration).
Thrombin converts plasminogen to plasmin, which
breaks down the cross-linked ﬁbrin into soluble ﬁbrin
degradation products. Tissue-type plasminogen acti-
vator (t-PA) is mainly responsible for the dissolution
of ﬁbrin formed in the circulation. Fibrinolysis can be
inhibited either by antagonizing plasmin through
alpha 2-antiplasmin or by PAIs. PAI-1, stored in the
alpha granules of platelets, is mainly responsible
for resistance to ﬁbrinolysis. Activation of protease-
activated thrombin receptor 1 by thrombin results
in synthesis and secretion of active PAI-1 from
aggregated platelets and thrombin activation of
TAFI, which inhibits the t-PA–mediated conversion
of plasminogen to plasmin. Plasma lipoprotein (a)
[Lp(a)], a homolog of plasminogen, can inhibit t-PA–
mediated plasminogen activation.
Measurement of individual proteins involved in
ﬁbrinolysis, as a surrogate marker of overall ﬁbrino-
lytic activity, can be undertaken using immunoassays.
Studies have focused on themeasurement of a number
of biomarkers of ﬁbrinolysis, including t-PA (25–30),
PAI-1 (31), alpha-2 antiplasmin, alpha2-antiplasmin-
plasmin complex (31), markers of ﬁbrin degradation
products (D-dimer and soluble ﬁbrin) (25,28,31), and,
more recently, TAFI (31) and Lp(a) (31,32).
Given the potential role of the ﬁbrinolytic system
in the pathogenesis of ACS, studies have attempted
to elucidate the relationship between plasma bio-
markers and incipient cardiovascular risk. The main
limitations of this approach are knowing the relative
importance and contribution of any biomarker to theoverall ﬁbrinolytic system at any given point,
knowing whether to measure levels or activity of
biomarkers, and the confounding association be-
tween ﬁbrinolytic markers and more established car-
diovascular risk factors (33,34). Overall, the outcome
of studies evaluating the role of plasma markers of
ﬁbrinolysis as independent predictors of cardiovas-
cular risk has been disappointing, with much con-
ﬂicting evidence and a number of positive studies
only demonstrating a weak association (31). This,
combined with methodological problems with the
assays, has resulted in greater emphasis being placed
on more global assays of ﬁbrinolytic activity.
EUGLOBULIN CLOT LYSIS TIME
The euglobulin fraction (containing the key activators
of the ﬁbrinolytic cascade, including plasminogen
activators, plasminogen, and plasmin) is precipitated
from citrated plasma and calcium is added to promote
clot formation. The time taken to lyse this clot is
utilized as a measure of ﬁbrinolytic activity (35,36).
This technique from the 1950s has now been super-
seded by more rapid, physiological tests of ﬁbrino-
lytic capacity.
THROMBOELASTOGRAPHY
TEG is a global test of coagulation status, simulta-
neously assessing clot development, stabilization,
and dissolution. Another related and commercially-
available technique is ROTEM (37,38). TEG utilizes a
pin suspended by a torsion wire into a cylinder to
measure the physical properties of a clot. The torsion
wire is connected to a mechanical-electrical trans-
ducer and relays information on the speed and
TABLE 2 Studies From 1999 to 2015 That Utilized Multivariate Analysis in Patient Cohorts >1,000 to Assess the Predictive Value of Plasma Fibrinolysis Markers for Adverse CV Events
First Author (Ref. #) Design Patients (n) Population Follow-Up Endpoint Results
Kinlay et al. (28) RCT 2,860 ACS patients enrolled
in MIRACL study
16 weeks CV events (death, nonfatal MI,
cardiac arrest, or worsening
angina)
t-PA antigen associated with increased
risk of CV events (HR: 1.25; p ¼ 0.0014).
his correlation was attenuated following
djustment for risk factors (HR: 1.14;
¼ 0.08)
Zamani et al. (106) RCT 2,925 ACS patients enrolled in
MIRACL study
16 weeks Death and recurrent nonfatal
ACS (MI or unstable angina)
t- antigen associated with primary
ndpoints, but after adjustment for
isk factors, HR fell from 1.90 to 1.27 for
eath (p ¼ NS), and HR 1.20 for
CS (p ¼ NS).
Wang et al. (66) Prospective 3,209 Subjects in 6th cycle of
Framingham Offspring
Study (1995–1998)
10 yrs Death and major CV events
(MI, unstable angina, heart
failure, and stroke) and
nonmajor CV events
M tiple biomarkers, including D-dimer
nd PAI-1. Following multivariate
djustment, HR for D-dimer associated
ith death was 1.24; 95% CI: 1.02–1.50;
¼ 0.03; and HR: 1.24 for PAI-1 in
elation to CV events (p ¼ 0.03).
Folsom et al. (34) Prospective 6,391 Subjects without
atherosclerosis
4.6 yrs Cancer death, mortality, and CAD
(MI or coronary death), and CV
disease (cardiac arrest, angina 
revascularization and stroke)
D imer, factor VIIIc and PAP not predictive
f CV disease, but independently
ssociated with cancer death and total
ortality. Following adjustment for risk
actors, mortality increased for each quartile
ncrement in D-dimer (33% increase;
5% CI: 15–54), factor VIIIc (26% increase;
5% CI: 11–44), and PAP (20% increase;
5% CI: 4–38) (p values not published).
May et al. (25) Prospective 3,582 Women without prior CAD 4.7 yrs Development of CV death, MI, or
coronary revascularization
D imer, t-PA antigen, and vWF were not
ssociated with development of CAD after
djustment for CV risk factors.
Cushman et al. (108) Nested case-
control study
5,201 (146
selected
cases)
Patients without baseline
vascular disease
2.4 yrs Coronary death, MI, and angina. D imer and PAP levels, but not PAI-1,
redicted MI or coronary death, but not
ngina. D-dimer values above median
ssociated with RR: 2.5; 95% CI: 1.1–5.9; and for
AP with RR: 3.1; 95% CI: 1.3–7.7, independent
f other risk factors.
Nordenhem et al. (107) Case-control
study
1,267 Patients with ﬁrst
MI identiﬁed
Matched to
control group
MI P ma t-PA/PAI-1 complex associated with
I, with synergistic interaction in
ale smokers (OR: 4.6; 95% CI: 3.3–6.5) or
iabetics (OR: 7.9; 95% CI: 3.9–16.1)
p values not published).
Smith et al. (64) Prospective 2,398 Men age 49–65 yrs 4 yrs CV events (coronary heart disease
and ischemic stroke combined)
A r adjusting for risk factors, ﬁbrinogen
HR: 1.26; p ¼ 0.005), D-dimer (HR: 1.34;
¼ 0.001) and PAI-1 (HR: 1.24; p ¼ 0.013)
ere independent risk factors for CV
vents. Factor VIIc was inversely related
o CV events (HR: 0.75; p ¼ 0.001).
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TABLE 2 Continued
First Author (Ref. #) Design Patients (n) Population Follow-Up Endpoint Results
Morange et al. (109) Prospective 1,057 Patients with CAD
(AtheroGene Study)
6.6 yrs CV death and nonfatal CV events
(MI and stroke)
vWF, ﬁbrinogen, TAT, D-dimers, and PAP were
all associated with CV death but not with
nonfatal CV events. After adjustment for
risk factors and CRP, only ﬁbrinogen and
D-dimer remained associated with CV death
(HR: 1.27; 95% CI: 1.04–1.55; p ¼ 0.019).
Tregouet et al. (110) Prospective 1,668 Patients with CAD
(AtheroGene Study)
2.3 years CV death and nonfatal CV
event (MI)
Activated TAFI independently associated with
risk of CV death (HR: 2.38; 95% CI: 1.56–3.63;
p < 0.0001), even after adjustment for risk
factors (HR: 1.69; 95% CI: 1.07–2.67; p ¼ 0.01).
Total TAFI not associated with CV events.
Gaw et al. (111) Prospective 5,732 Elderly patients with risk
factors for, or established
vascular disease
3.2 yrs CV death, nonfatal MI, fatal or
nonfatal stroke
Lp(a) levels not associated with primary
endpoint (HR: 1.05; 95% CI: 1.00–1.11; p ¼ NS).
Bennet et al. (112) Case-control study 2,047 Patients without CAD or stroke at
baseline who experienced an
MI or coronary death
NA First-ever MI or coronary death Lp(a) values in the top vs. bottom third, after
multivariate adjustment for CV risk factors,
OR: 1.60; 95% CI: 1.38–1.85 (p values not
published). Progressive increase in OR with
higher Lp(a) levels.
Willeit et al. (91) Prospective case-
control study
1,925 Patients without CV disease
who experienced MI or
coronary death
19.4 yrs First-ever MI or coronary death OR for D-dimer was 1.08 (p ¼ 0.019), OR for
t-PA antigen 1.05 (p ¼ 0.167). and OR for
Lp(a) 1.24 (p < 0.001).
Wannamethee et al. (92) Prospective study 3,217 Men age 60–79 yrs without CAD 7 yrs Coronary death, nonfatal MI, and
uncomplicated angina
After adjustment for risk factors, D-dimer
associated with MI/coronary death
(HR: 1.18; p ¼ 0.02), but not with angina
(HR: 0.93; p ¼ NS).
Chien et al. (93) Prospective
cohort study
3,484 Chinese patients without CAD 13.8 yrs All-cause death, stroke, and CAD Lp(a) levels did not correlate with risk of
CV disease (HR: 0.81; p ¼ NS).
Gurdasani et al. (94) Prospective
cohort study
18,720 Healthy subjects, age 39–79 yrs 11.4 yrs Peripheral artery disease, stroke,
and CAD-related events
Lp(a) levels associated with CAD
hospitalization and mortality (HR: 1.13;
p < 0.00001).
Nestel et al. (95) Prospective study 7,863 Patients with prior coronary event 6 yrs Coronary death, nonfatal MI,
ischemic stroke, revascularization,
total CV events, and total
coronary events
Lp(a) levels correlated with CV events
(p < 0.001), total CV events (HR: 1.23;
p ¼ 0.002), and coronary events
(p ¼ 0.03).
Kwon et al. (96) Prospective 1,494 Type 2 diabetic patients with CAD 4.4 yrs MACE (cardiac deaths and
nonfatal MI)
Highest Lp(a) level tertile associated with
MACE (HR: 2.89; p ¼ 0.005).
Kwon et al. (97) Prospective 6,252 Patients with suspected CAD 3.1 yrs MACE (cardiac death and
nonfatal MI)
Elevated Lp(a) associated with MACE
(HR: 1.773; p ¼ 0.005).
Canoui-Poitrine et al. (100) Prospective
cohort study
9,711 Men age 50–59 yrs free of CAD
and stroke
10 yrs CAD events (angina, MI, and
coronary death) and
ischemic stroke
Lp(a) levels associated with CV events
(HR: w1.2; p ¼ 0.001) after adjustment
for risk factors.
Virani et al. (101) Prospective 13,318 (n ¼ 3,467
blacks, n ¼ 9,851
Caucasians)
African-American and Caucasian
adults without CHD or stroke
20 yrs CV events (coronary death, MI,
silent MI, revascularization)
and stroke
Lp(a) levels associated with CV events.
Quintile analysis for the highest
compared with the lowest quintile
demonstrated an HR: 1.35 (p ¼ 0004)
for blacks and HR: 1.27
(p ¼ 0.001) for whites.
O’Donoghue et al. (102) Prospective 6,708 Patients with CAD from 3
studies (PEACE, CARE, and
PROVE-IT-TIMI 22 trial)
MACE (composite of CV death,
MI, or stroke)
No association between Lp(a) levels and MACE
in any of the 3 trials individually or
combined.
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1690dynamics of clot formation. As blood clot formation
occurs around the pin, ﬁbrin strands form between
the cylindrical cup and pin. With additional rotation
of the cylindrical cup, this is transmitted to the pin
and the resulting mechanical-electrical transduction
is depicted in a numerical and graphical representa-
tion. With the ROTEM technique, movement is in-
stead generated from the oscillation of the pin/wire
transduction system, while the cup is held immobile
and an optical detection system is utilized to trans-
duce the signal. TEG can be modiﬁed to use a variety
of different activators and inhibitors to provide in-
formation on speciﬁc components of the coagulation
system, including platelet function testing and ﬁbri-
nolytic status (38–45). In ﬁbrinolysis assessment, TEG
is typically compared in the presence and absence of
the ﬁbrinolysis inhibitor aprotinin (37,46). Table 1
shows the features of thromboelastography and how
these compare with the GTT.
There are a number of important limitations to the
use of TEG as a clinical tool to assess global throm-
botic status. TEG was originally designed for native,
nonanticoagulated blood (47), but subsequent modi-
ﬁcations have included the use of activators of coag-
ulation and additional reagents to evaluate speciﬁc
components of hemostasis (38,47). This has helped
standardize the initiation of coagulation, but does not
reﬂect a patient’s physiological state. Although TEG is
a useful tool for assessing bleeding risk, for example
in cardiac surgery, its practical value in assessing the
(spontaneous) thrombolytic status of patients or the
effect of medications is questionable. The shortcom-
ings of this technique begin with the testing of
citrated and recalciﬁed blood. The effect of extracel-
lular calcium concentration on coagulation indexes
and thromboelastography results is signiﬁcant (48).
There are signiﬁcant differences in TEG results be-
tween fresh native whole blood and recalciﬁed citra-
ted whole blood (49,50) and the correlation between
TEG results performed on kaolin- versus nonkaolin-
activated native and citrated blood is poor (51).
In the absence of shear or any other platelet-
activating stimuli, clot formation can be initiated
either by intrinsic (kaolin, ellagic acid) or extrinsic
(tissue factor) activators, and the test results vary
accordingly. However, the major limitation of TEG is
that it fails to assess the procoagulant (thrombin-
generating) and ﬁbrinolysis-inhibiting (PAI-1; TAFI)
properties of platelets. Furthermore, the use of gentle
rotation of a cylindrical cup more closely resembles
the low shear stress environment encountered with
venous stasis and does not reﬂect the high-shear
situation in stenosed arteries. Furthermore, this
mitigates the contribution of platelet activation and
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1691subsequent thrombin generation, which play key
roles in arterial thrombogenesis.
TEG results have only demonstrated a weak cor-
relation with standard tests of coagulation (52), with
no formal validation or standardization (53) and sig-
niﬁcant interlaboratory variability; coefﬁcients of
variation range between 8% and 40% for TEG and up
to 4% to 84% for ROTEM (54). Due to the problems
with standardization and determination of normal
reference values, TEG is better utilized as a measure
of the change in coagulation status over time, when a
patient’s baseline results are already known (55).
Despite these limitations, TEG beneﬁts from its
availability as a point-of-care test, providing rapid
information on the coagulation proﬁle of patients.
GLOBAL THROMBOSIS TEST
The GTT is a newer point-of-care test that simulta-
neously assesses platelet reactivity, thrombosis,
and thrombolytic activity, from a single, non-
anticoagulated blood sample (56,57). This techniqueTABLE 3 Clinical Studies Evaluating the GTT in the Prediction of Card
First Author (Ref. #) Population Patients (n)
Sharma et al. (60) End-stage renal disease
patients on hemodialysis
216
Saraf et al. (61) ACS patients receiving dual
antiplatelet therapy
300
Saraf et al. (61) ACS vs. healthy
control subjects
300
Suehiro et al. (75) Healthy subjects of smoking
and nonsmoking status
Smokers ¼ 76 vs.
nonsmokers ¼ 63
Ikarugi et al. (76) Healthy young males
and elderly males
Young ¼ 30 vs.
elderly ¼ 34
Suehiro et al. (77) Males with MetS vs.
control subjects
MetS ¼ 30 vs.
control ¼ 53
Rosser et al. (98) ACS or stable coronary disease
randomized to vorapaxar vs.
placebo, in addition to
standard of care
57
Taomoto et al. (99) Acute cerebrovascular
disease (CVA) vs.
healthy control subjects
CVA ¼ 185
control subjects ¼ 19
CVA ¼ cerebrovascular accident (stroke); LT ¼ lysis time; MetS ¼ metabolic syndrome;utilizes native, nonanticoagulated blood that is free
of any external agonists (Table 1). Platelets become
activated by the high shear stress generated by the
passage of blood through a conical tube containing
narrow gaps. The predominant stimulus for platelet
activation in severely-narrowed atherosclerotic cor-
onary arteries is pathologically high shear stress
(>10,000 s1), which leads to rapid platelet activa-
tion. The GTT mimics this pathological environment
to provide high shear stress as the primary stimulus
for platelet aggregation, platelet microparticle, and
thrombin generation, resulting in occlusive thrombus
formation (58,59). The time taken for an occlusive
thrombus to form in the space downstream, reﬂecting
platelet aggregation and initiation of coagulation, is
manifested in the arrest of ﬂow as detected by an
optical sensor, and is termed the occlusion time
(OT, s). The restart of blood ﬂow, due to spontaneous
dissolution of the formed thrombus, represents
endogenous thrombolytic activity and is recorded
again by an optical sensor and termed the lysis time
(LT, s).iovascular Risk
Follow-Up Methods Primary Endpoint Results
276  166 days GTT MACE (CV death,
nonfatal MI, CVA,
and peripheral
arterial thrombosis)
Impaired endogenous thrombolysis
(LT >3,000 s) strongly associated
with MACE (HR: 4.25; p ¼ 0.004),
nonfatal MI, and CVA (HR: 14.28;
p ¼ 0.0 ¼ 1) and peripheral
thrombosis (HR: 9.08;
p ¼ 0.003)
12 months GTT MACE (CV death,
nonfatal MI,
or CVA)
LT >3,000 s was an independent
predictor of MACE (HR: 2.52;
p ¼ 0.004) and CV death (HR: 4.2;
p ¼ 0.033).
N/A GTT MACE (CV death,
nonfatal
MI, or CVA)
OT prolonged in ACS (428 s vs. 378 s;
p < 0.001) and LT shorter in ACS
(1,053 s vs. 1,362 s; p < 0.001) than
in control subjects
3 months GTT Effect of smoking on
thrombotic proﬁle
LT was signiﬁcantly longer in smokers
than in nonsmokers (1,794 s vs.1,530 s;
p ¼ 0.029) with no signiﬁcant
difference in OT
N/A GTT Effect of age, smoking,
and exercise on
thrombotic proﬁle
LT was signiﬁcantly longer in elderly vs.
young (p < 0001), and prolonged in
elderly smokers than nonsmokers
(p < 0.001)
N/A GTT Comparison of
thrombotic proﬁle
between groups
LT signiﬁcantly longer in MetS than in
control subjects (1,494 s vs. 1,246 s).
PAI-1 level correlated with LT
(p < 0.01)
N/A GTT Thrombotic status,
as shown by OT
and LT of GTT
Vorapaxar treatment prolonged OT
(561 s vs. 372 s; p ¼ 0.003) and
shortened LT (1,158 s vs. 1,733 s;
p ¼ 0.016)
5
N/A GTT Thrombotic status,
as shown by OT
and LT of GTT
In stroke patients, OT was shorter
(p < 0.0001) and LT was longer
(p < 0.0001) than in healthy
control subjects
OT ¼ occlusion time; other abbreviations as in Tables 1 and 2.
TABLE 4 Studies Utilizing TEG in the Evaluation of Platelet Reactivity and its Correlation to the Risk of Ischemic Events in Nonsurgical Cardiovascular Patients
First Author (Ref. #) Population Patients (n) Follow-Up Method Primary Endpoint Results
Jeong et al. (113) PCI-treated patients receiving
aspirin and clopidogrel
197 24 months MA-thrombin TEG
measurements,
conventional
aggregometry, and
genotyping
Relationship between MA-
thrombin on high on-
treatment platelet ctivity
(HPR) and long-te ACE
HPR and high MA-thrombin
were both independently
associated with MACE (HR:
3.09 and 2.24, respectively).
The combination of both
increased HR for MACE to
5.56; p ¼ 0.0002. High MA-
thrombin also predicted the
risk for HPR (OR: 13.89;
p < 0.001)
Gurbel et al. (114) Patients undergoing PCI and
taking aspirin and clopidogrel
225 36 months ADP-induced (MA-ADP)
and thrombin-induced
(MA-thrombin) TEG
measurement and LTA
Prediction of long-ter vent
occurrence (ischem nd
bleeding) followin enting
Patients with ischemic events
had higher MA (ADP), MA
(thrombin), and LTA (p <
0.0001 for all), which were
independent predictors of
ischemic events at 3 years
(HR: 10.3, 3.8, and 4.8,
respectively; all p < 0.0001)
Tang et al. (115) Patients undergoing PCI divided
into 3 groups depending on
inhibition rates to aspirin and
clopidogrel (n ¼ 90): control
group (n ¼ 30) and resistance
group (n ¼ 60), who were then
randomized to 2 subgroups
(R þ R and R þ L) to receive
different antiplatelet
combinations
90 12 months TEG Occurrence of CV isch c events
(including stent th bosis,
recurrent unstable ina,
and MI)
Patients resistant to antiplatelet
therapy vs. nonresistant
control groups, had an
increased risk of stent
thrombosis (20% vs. 3%),
recurrent unstable angina
(36% vs.10%), and (MI 17%
vs. 1%; p < 0.01).
Randomization to a loading
dose regimen improved
inhibition rates and reduced
the rates of CV events
(p < 0.01)
Gurbel et al. (116) Patients undergoing PCI 84 24 months TEG and conventional
aggregometry.
Biomarker evaluation
with ﬂuorokine
multianalyte proﬁling
Thrombogenicity and arkers
of inﬂammation a
correlation to the rrence
of ischemic events
Patients with high MA had an
ischemic event more often
than patients with low MA
(48% vs. 13%; p ¼ 0.02).
Those in the highest MA
group demonstrated higher
levels of CRP, IL-8, and
epidermal and vascular
endothelial growth factors.
Gurbel et al. (117) Patients undergoing
nonemergent PCI
192 6 months ADP-induced LTA and
TEG
Platelet reactivity and t
strength and the r f post-
discharge ischemic nts
Patients experiencing ischemic
events (n ¼ 38)
demonstrated higher
platelet reactivity by LTA
(63  12% vs. 56  15%;
p ¼ 0.02), higher clot
strength (MA) (74  5 mm
vs. 65  4 mm; p ¼ 0.001)
and more rapid ﬁbrin
generation (4.3  1.3 min vs.
5.9  1.5 min; p ¼ 0.001)
Continued on the next page
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TABLE 4 Continued
First Author (Ref. #) Population Patients (n) Follow-Up Method Primary Endpoint Results
Bliden et al. (118) Patients receiving aspirin (325 mg
qd) and clopidogrel (75 mg qd)
undergoing nonemergent PCI
100 12 months Measurement of platelet
aggregation by
standard LTA and TEG
Correlation between heightened
platelet aggregation and
occurrence of ischemic events
High on-treatment platelet
reactivity, as measured by
aggregometry and TEG,
were signiﬁcantly related to
ischemic events (p ¼ 0.001
for both assays).
Gurbel et al. (119) African-American and Caucasian
patients undergoing
elective PCI
252 6 months TEG Assess race and sex difference in
thrombogenicity and relate
this to adverse ischemic events
TEG-derived platelet clot
strength measurements (RR:
2.52; p ¼ 0.017) and sex
(RR: 2.56; p ¼ 0.009) as
independent predictors of
ischemic events. African-
American women exhibited
higher thrombogenicity than
the other race and sex
groups (p < 0.05)
Kreutz et al. (24) Patients with coronary artery
disease, treated with aspirin
and clopidogrel
211 3  1.9 yrs Platelet aggregometry
assessed by LTA and
clot formation using
TEG. Genotyping of
Val34Leu using
TaqMan assay
Evaluate effects of Val34Leu on
ﬁbrin generation, platelet
aggregation, and long-term
clinical outcomes
Homozygous carriers of 34Leu
variant had the greatest risk
of MI and CV death (p ¼
0.002), associated with
reduced ﬁbrin clot formation
time (TEG K: 1.27  0.3 min
vs. 1.68  1.1 min;
p ¼ 0.011).
Tang et al. (120) Chinese patients undergoing
PCI for ACS
577 12 months Detection of CYP2C19
G681A and P2Y12
C34T polymorphisms
by ligase detection
reaction. Platelet
reactivity assessed by
TEG
Clopidogrel responsiveness and
MACE (CV death, nonfatal MI,
target vessel revascularization,
and stent thrombosis)
118 patients with mutational A
allele of CYP2C19 and
mutational T allele of P2Y12
demonstrated lowest ADP
inhibition (49.74  32.61%)
and highest prevalence of
clopidogrel low response
(29.7%), which correlated
with the highest CV event
rates (8.5% vs. 1.5%).
Wu et al. (121) NSTEMI patients
undergoing PCI
233 24 h CYP2C19*2 and *3 LOF
alleles were evaluated
using DNA microarray
method. Platelet
reactivity assessed
by TEG
CYP2C19 genotype on HPR and
risk of periprocedural MI
HPR more frequent in patients
with periprocedural MI and
an independent risk factor
following multivariate
analysis (OR: 4.348; p ¼
0.001). HPR also correlated
with 2 CYP2C19 LOF allele
carriage, associated with a
3-fold increased risk
(p ¼ 0.037).
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1694Because the GTT assesses both thrombus formation
and thrombus lysis in native blood, without external
agonists and using high shear, it is arguably the most
physiological assessment of global thrombotic status
currently available.
This test has been studied in patient groups at high
risk of cardiovascular thrombosis, with early results
suggesting that it may be useful in predicting clinical
outcomes (60,61). It has not been compared with
other platelet function tests or TEG. However, the
results would not be expected to correlate because of
the different ﬂows (high vs. low shear stress) and the
use of native versus anticoagulated blood (Table 1).
ENDOGENOUS FIBRINOLYSIS:
EVIDENCE FOR AN IMPORTANT ROLE
IN CARDIOVASCULAR DISEASE
PLASMA MARKERS OF FIBRINOLYSIS IN CARDIO-
VASCULAR DISEASE. A number of studies have
attempted to examine the relationship between
plasma markers of ﬁbrinolysis, signifying impaired
ﬁbrinolysis, and the occurrence of cardiovascular
events.
Genetic polymorphisms in key enzyme regulators
of ﬁbrinolysis may increase susceptibility to throm-
botic events (62). The 4G4G phenotype of the 4G/5G
PAI-1 gene polymorphism was found to be an inde-
pendent predictor of AMI (odds ratio: 2.7, p ¼ 0.002)
(63), and was observed more frequently in patients
with a previous history of AMI than in those with
stable angina. A review of the prospective studies
undertaken between 1999 and 2009, encompassing
some 45 studies and nearly 50,000 patients, demon-
strates the conﬂicting results regarding the useful-
ness of these markers (31). Most of these were large
epidemiological studies assessing thousands of pa-
tients. Table 2 summarizes publications between 1999
and 2015 that utilized multivariate analysis in patient
cohorts >1,000 to assess the predictive value of
plasma ﬁbrinolysis markers for adverse cardiovascu-
lar events.
In 1 of the larger prospective studies that evaluated
t-PA levels in 3,582 women, there was a weak corre-
lation between t-PA and the development of coronary
artery disease (25). In patients with established cor-
onary disease or AMI, t-PA levels were predictive of
future cardiovascular events. In the Caerphilly Study
of 2,398 men with 13 years of follow-up, baseline PAI-
1 levels were signiﬁcantly associated with cardiovas-
cular risk (64), but after multivariate analysis, the
correlation became nonsigniﬁcant (64). Other studies
evaluating PAI-1 demonstrated a signiﬁcant associa-
tion with coronary events (65), cardiogenic shock,
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(MACE) (32). In the Framingham study involving
3,209 participants, PAI-1 levels were not related
to cardiovascular events (66). Other studies have also
failed to demonstrate a prognostic role for base-
line t-PA or PAI-1 levels (27,28). There is also con-
ﬂicting data from studies on the role of other plasma
markers of ﬁbrinolysis, including D-dimer assays
(25,28,31,64), plasmin-alpha2-antiplasmin complex
measurements (31), TAFI (31), and Lp(a) levels (31,32).
Even allowing for publication bias, in that negative
studies are less likely to be published, it is clear that
biomarkers of ﬁbrinolysis may, at best, allow a weak
prediction of increased cardiovascular risk at a pop-
ulation level only. It is difﬁcult to ascertain global
ﬁbrinolytic status on the basis of the plasma level of 1
or even several biomarkers. Furthermore, there is still
controversy regarding the ideal laboratory technique
to use. Determination of the total antigen levels
of plasma markers can be achieved using enzyme-
linked immunosorbent assays; alternatively, mea-
surement of speciﬁc biological activity levels of
plasma markers can be undertaken with immuno-
functional chromogenic substrate kinetic assays.
With some plasma markers, such as PAI-1, which has a
relatively long half-life (approximately 1 h), there is
likely to be a good correlation between PAI-1 antigen
and PAI-1 activity levels. However, a poor correlation
has been demonstrated between measurements of
TAFI antigen and TAFI activity (67), which may be a
reﬂection of its short half-life (approximately 10 min).
These problems with plasma marker measure-
ments are confounded by the additional role of
complementary pathways involved in mediating
endogenous ﬁbrinolysis. Studies have demonstrated
the importance of plasma ﬁbrin architecture in facil-
itating effective endogenous ﬁbrinolysis (68) (Central
Illustration). Additionally, the release of proteolytic
enzymes from thrombus-associated neutrophils,
namely elastase, has been shown to result in direct
digestion of ﬁbrin and inactivation of PAI-1 (69)
(Central Illustration). Moreover, thrombus-adherent
monocytes have been demonstrated to enhance
TAFI activity, reducing ﬁbrinolytic activity and pro-
tecting against clot lysis (70).
Platelets represent an important source of PAI-1,
containing up to 90% of the total PAI-1 content of
blood (71). During thrombus formation, activated
platelets release high local concentrations of PAI-1,
which serve to inhibit thrombolysis and stabilize
clot formation (Central Illustration). The most func-
tionally important source of PAI-1 is, therefore,
platelets, and this pool of PAI-1 varies independently
of plasma PAI-1 levels (72–74).These studies have highlighted that regulation of
thrombus formation is a dynamic, multifaceted phe-
nomenon, and measurements of individual compo-
nents of the pathway do not give an accurate
reﬂection of this complex system.
GTT IN CARDIOVASCULAR DISEASE. Because the
balance between prothrombotic factors and endoge-
nous thrombolytic activity determines the propensity
for thrombus formation in ACS, an overall assessment
of thrombotic risk requires a global evaluation of a
patient’s thrombotic proﬁle, including platelet reac-
tivity, activation of the coagulation system (thrombin
generation), and endogenous ﬁbrinolysis.
Clinical studies evaluating the GTT are shown in
Table 3. A study of 300 patients with ACS (61)
revealed that although platelet reactivity was
reduced, endogenous thrombolysis was impaired in
ACS patients compared with healthy volunteers,
despite taking dual antiplatelet medication. There
was no correlation between OT and MACE. Some 23%
of ACS patients had a markedly prolonged LT, a
ﬁnding that was not demonstrated in normal sub-
jects. Impaired endogenous thrombolysis was an in-
dependent predictor of MACE. LT >3,000 s was
identiﬁed as the optimal cutoff point to predict
MACE; above this level, the hazard ratio for cardio-
vascular events increased as the LT increased. LT
remained a statistically-signiﬁcant predictor for
MACE, even after adjustments for a number of base-
line cardiovascular risk factors.
The GTT has also been used to assess the thrombotic
proﬁle of patients with established cardiovascular risk
factors. LT was signiﬁcantly prolonged in smokers
compared with nonsmokers, whereas no signiﬁcant
difference in OT was observed (75). There was a direct
correlation between LT and daily cigarette consump-
tion. Following 3 months of smoking cessation, LT
values were found to be signiﬁcantly shorter when
compared with baseline GTT measurements. Another
study demonstrated impaired endogenous thrombo-
lytic activity in elderly male patients and in those who
smoked, but showed no difference in OT (76), sug-
gesting that the increased susceptibility of smokers to
thrombosis may, in part, be related to decreased
ﬁbrinolytic activity. In patients with metabolic syn-
drome, LT was signiﬁcantly prolonged compared with
normal volunteers, and was associated with signiﬁ-
cantly higher PAI-1 levels, although no difference was
observed in OT (77).
Patients with end-stage renal disease (ESRD) are at
much higher cardiovascular risk than the general
population (60,78), and impairment of endogenous
ﬁbrinolytic activity has also been observed, with
reduced t-PA secretion and elevated levels of
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demonstrated signiﬁcantly prolonged OT and LT
compared with normal volunteers (60). Additionally,
42% of patients demonstrated an LT >3,000 s and
34% demonstrated markedly impaired ﬁbrinolytic
status with LT >6,000 s, compared with none of the
control subjects. LT was strongly predictive of the
composite of cardiovascular death, nonfatal myocar-
dial infarction, cerebrovascular events, and periph-
eral thrombotic events, even after adjustment for
baseline variables. No relationship between OT and
MACE was observed.
TEG IN CARDIOVASCULAR DISEASE. TEG has been
applied to guide the use of blood and blood products
during trauma resuscitation (80) and liver and cardiac
surgery (81,82), and, more recently, it has also been
evaluated in obstetric patients (83). It has now been
reliably demonstrated that TEG detects hyper-
ﬁbrinolysis in the perioperative and trauma setting
(84,85), with increasing evidence that TEG-guided
algorithms can help to optimize patient manage-
ment (82,86). Its indications for use in the assessment
of cardiovascular patients are ever expanding,
including the monitoring of patients on aspirin, clo-
pidogrel, and glycoprotein IIb/IIIa antagonists
(87,88). A number of studies have demonstrated that
TEG-derived measurements of platelet responsive-
ness can be utilized as a prognostic marker to predict
the risk of long-term ischemic events (Table 4).
However, TEG has proven to be a less robust mea-
sure of hypoﬁbrinolysis, with unmodiﬁed TEG assays
in normal subjects exhibiting only a minor degree of
ﬁbrinolysis. Indeed, in 1 study, the normal range of
ROTEMmaximum lysis at 60min was demonstrated to
be <12% (range 0% to 12%) (89). The current limitation
with existing TEG techniques to evaluate hypoﬁ-
brinolysis has prompted the development of novel
methods to improve its sensitivity. These techniques
have included the use of exogenous urokinase or t-PA
in concentrations that allow for the assessment of clot
formation, whilst simultaneously enhancing clot lysis,
permitting more accurate assessment of hypoﬁ-
brinolysis (90). However, there has been no formal
standardization and very little published data on these
approaches, and further work is required to improve
the sensitivity and standardization of TEG techniques
to evaluate hypoﬁbrinolysis.A large number of studies have evaluated the
usefulness of TEG in assessing clot strength. In this
regard, TEG has been shown to be very useful in
predicting increased cardiovascular risk in patients
with established coronary disease and in those
undergoing percutaneous coronary intervention
(Table 4).
CONCLUSIONS
Although previously viewed as a secondary phe-
nomenon in response to the formation of thrombi, a
large body of evidence now points to a much
more prominent role for endogenous ﬁbrinolysis in
thrombus formation.
The technical limitations, difﬁculty in interpreta-
tion, and conﬂicting data regarding prognostic use-
fulness of plasma markers in patients with coronary
disease limit their adoption into clinical practice.
Recognition of these limitations prompted the de-
velopment of global assays of ﬁbrinolytic status. TEG
is a useful tool for assessing bleeding risk, and has
also been used to assess clot strength, which has
been shown to predict future cardiovascular events.
However, its practical value in assessing the (spon-
taneous) thrombolytic status of patients or the effect
of medications is questionable, due to its inability to
assess the procoagulant and ﬁbrinolysis-inhibiting
properties of platelets and its low shear-stress mi-
lieu, which more closely resembles venous ﬂow. The
GTT provides a physiological assessment of global
thrombotic status by assessing both thrombus for-
mation and thrombus lysis in native blood in a high-
shear setting that is relevant to arterial ﬂow. Early
clinical studies suggest that it may be useful in
identifying patients at risk of future cardiovascular
events. Endogenous ﬁbrinolysis, until recently a
poorly-understood area, represents an expanding
and exciting area for identifying patients at in-
creased cardiovascular risk and as a potential
target for pharmacological modulation to improve
outcomes.
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